No abstract

Background: Orsomucoid protein A (ORM) is a major acute-phase protein. Serum ORM (se-ORM) protein A elevates in infections, malignancies, and autoimmune diseases. Urinary ORM (u-ORM) protein A is more accurate and less invasive marker of inflammation. Elevated u-ORM was associated with pathomechanism factors related to psoriasis such as endothelial dysfunction; however, the clinical significance of it has not been explored yet. Aim: To evaluate se-ORM/u-ORM protein A and urinary orsomucoid protein A/urinary creatinine (u-ORM/u-CREAT) in patient with psoriasis and their relations to severity of the disease. Methods: This case-control study was conducted at Dermatology and Andrology Department; 35 psoriasis patients and 35 age-and sex-matched healthy controls were included. They were subjected to history taking and general and dermatological examination. Psoriasis severity was assessed by Psoriasis Area and Severity Index (PASI) score. Measurement of se-ORM/u-ORM protein A using ELISA and u-ORM/u-CREAT using colorimetric method.Results: Highly significant difference between psoriasis patients and controls regarding u-ORM protein A level (p value = 0.01). It was also higher in severe cases than moderate and mild ones and higher in moderate than mild cases (p value 0.001, 0.001, and 0.004, respectively). There were significantly higher u-ORM/u-CREAT (p ˂ 0.001) levels in psoriasis patients than in controls. Also, significantly higher U-ORM/u-CREAT levels were found in severe psoriasis cases than in mild and moderate cases (p = 0.003 and 0.006, respectively). While the se-ORM levels showed no significant differences between the studied groups.Conclusion: u-ORM/u-CREAT is a highly sensitive, easily available, and new inflammatory biomarker of psoriasis which correlates to the disease severity.

Introduction Female sexual dysfunction (FSD) refers to a problem that occurs during the sexual response cycle that prevents the female from experiencing satisfaction from sexual activity. It is a multifactorial condition established in biological, psychosexual, and interpersonal factors. It is divided into four groups: sexual desire, arousal, orgasmic, and pain disorders. Psoriasis and vitiligo although being of different pathogenesis and clinical presentation, both of them are common chronic skin diseases associated with significant disfigurement and systemic comorbidities like cardiovascular disease in psoriasis and endocrinal diseases like diabetes mellitus and thyroid disorders in vitiligo. They can affect sexuality through both psychological and biological factors. Objective To evaluate the effect of psoriasis and vitiligo on female sexual function in a sample of Egyptian patients in a hospital-based study. Patients and methods This study included 150 participants: 50 psoriatic women, 50 women with vitiligo, and 50 age-, sociocultural level (degree of education, occupation, religion, and residence)-, BMI-, and marital history-matched normal women as a control group. Sexual activity was estimated by using an Arabic translation of the female sexual function index questionnaire. Results This study revealed that FSD in psoriasis and vitiligo female groups was higher than that in the control group (with P=0.027 and 0.005, respectively). There was no significant difference regarding sexual dysfunction in cases with associated comorbidities and cases with only psoriasis or vitiligo. Among psoriasis group, FSD was significantly associated with older age (P=0.017), progressive course (P=0.008), long disease duration (P=0.013), and psoriasis severity as assessed by psoriasis area and severity index (P<0.001). Among vitiligo group, FSD was significantly associated with the duration of marriage (P=0.023), progressive course (P=0.001), genital affection (P=0.015), acrofacial type (P=0.011), vitiligo severity as assessed by vitiligo area and severity index (P=0.01), and vitiligo activity as assessed by vitiligo disease activity score (P=0.015). Conclusion The authors concluded that the psychological burden of psoriasis and vitiligo can adversely affect sexuality.

Background Psoriasis is a chronic, immune‐related disorder; inflammation, higher rate of epidermal proliferation, and angiogenesis are the main pathognomonic features. Cluster of differentiation 93 (CD93), an angiogenic element, plays a role in cell adhesion regulation and has a putative function in inflammation. Objective To assess CD93 immunohistochemical expression in psoriatic skin and the association of CD93 single nucleotide polymorphisms (SNPs) rs2749817 to disease pathogenesis and severity. Methods This case‐control study was done on 50 patients with psoriasis vulgaris beside 50 age‐ and sex‐matched healthy controls. Assessment of psoriasis severity was done by Psoriasis Area and Severity Index (PASI) score. 3 mm punch skin biopsies were taken from every participant, and hematoxylin and eosin staining and immunohistochemical staining for CD93 antibody were done. Assessment of CD93 rs2749817 gene polymorphism by the TaqMan allelic discrimination assay technique (real‐time PCR) was done. Results Immunohistochemical expression of CD93 showed membrano‐cytoplasmic localization in both endothelial and inflammatory cells of cases and controls with significant more positivity in dermal endothelial and inflammatory cells of cases than controls (p = 0.001 and 0.014 respectively). Strong intensity was present in 18 of cases endothelial cells and 24 inflammatory cells with absence in controls (p =  0.001 for both) with significantly higher H‐score and higher percent of positive cells (p  =  0.001 for both). The TC genotype was lower in patients compared to control (p‐value = 0.006) and CC genotype which was present only in cases (p‐value = 0.021). Conclusion Cluster of differentiation 93 has an essential role in psoriasis and an encouraging future therapy for psoriasis.

No abstract